|
Miraculins Inc.,
a biotechnology company dedicated to the discovery and validation of cancer
biomarkers for use in developing diagnostic tools and therapeutic products,
announced today that it does not intend to formalize its offer to combine with
IBEX Technologies Inc.
Read More
|
|
Miraculins Inc.,
a biotechnology company dedicated to the discovery and validation of cancer
biomarkers for use in developing diagnostic tools and therapeutic products,
today announced that it intends to make an unsolicited offer to acquire all
outstanding common shares of IBEX Technologies Inc.
Read More
|
|
Miraculins Inc.,
a biotechnology company dedicated to the discovery and validation of cancer
biomarkers for use in developing diagnostic tools and therapeutic products,
is pleased to announce that it has begun the validation study for its gastric
cancer biomarkers.
Read More
|
|
Miraculins Inc.,
a biotechnology company, dedicated to the discovery and validation of cancer
biomarkers for use in developing diagnostic tools and therapeutic products,
is pleased to announce that it has appointed the international law firm Hogan
& Hartson of Washington DC, to provide legal and strategic advice concerning
the FDA approval process for the Company's prostate cancer diagnostic product.
Read More
|
|
Miraculins Inc.,
a biotechnology company dedicated to the discovery and validation of cancer
biomarkers for use in developing diagnostic tools and therapeutic products,
is pleased to announce that it has successfully detected the primary protein
biomarker from its prostate cancer diagnostic, using an ELISA based immunoassay.
Read More
|
|
|